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The mainstay of the diagnosis of asthma is the presence of reversible airway obstruction.
Exhaled NO levels are increased in asthma, in close relationship with the amount of airway
inflammation, and may be used for monitoring the disease and adjusting therapy. In this study
we investigated the role of eNO as a diagnostic for asthma, compared with the FEV1-revers-
ibility and the PC20 (20% decrease of the FEV1 in the bronchial histamine provocation test),
in two independent centers, on an unselected population. ENO measurements were performed
with chemoluminesence technique in one center and with an electrochemical device in the
other. Only after correction for so-called nuisance factors (allergy, use of inhaled steroids,
recent infection, smoking, sex and the use of nitrate food) the eNO appeared as a diagnostic
with equal power as the FEV1-reversibility and the PC20.
Therefore, screening for asthma in our study population, with the eNO measurement, is
a simple, fast and safe strategy.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Asthma is a chronic inflammatory disorder, characterised by
recurrent respiratory symptoms against a background ofHospital, Department of
oofddorp, The Netherlands.
221.
van der Lee).
9 Elsevier Ltd. All rights reservedincreased bronchial responsiveness to external stimuli, giving
rise to variable airflow limitation which is reversible either
spontaneously or with treatment.1 Asthma is very common in
Europe, its prevalence in young adults is estimated about
20%.2 Diagnosis of asthma is based on symptoms and evidence
of reversible airway obstruction, shown in pulmonary func-
tion tests. This may not always be straightforward and
sometimes confirmation is needed by bronchial provocation
tests (histamine or metacholine provocation tests). These
tests are time-consuming and constitute a certain risk for
patients as they can lead to severe bronchoconstriction..
802 P. Munnik et al.Exhaled NO (eNO) is increased in patients with asthma
and can be used to monitor the therapeutic settings in
asthma.3,4 ENO also harbors the potential to serve as
a diagnostic separating asthma from non-asthma.5 The
measurement of eNO is easy and safe to perform in both
adults and children; most school-aged children are able to
perform the test.6 Airway eosinofilia, eNO and bronchial
hyperresponsiveness are well correlated, as all are influ-
enced by the same inflammatory process.6,7 ENO levels are
a strong predictor for steroid responsiveness in subjects
with undiagnosed respiratory symptoms.8 In a general
population, eNO levels are strongly correlated with atopy.9
Replacement of provocation tests by an eNO measurement
would be advantageous, because the eNO test is quicker to
perform and induces no bronchoconstriction.
The diagnostic role of eNO, however, is not well defined.
Many researchers only correlated parameters, but did not
test the equivalence of eNO to other diagnostic tests.10,11
Especially comparisons of the histamine provocation test
and eNO are scarce and suffer from spectrum or selection
bias.12,13 Therefore, data generated by these studies
cannot simply be extrapolated to a population of possible
asthmatics. In most studies with asthmatic subjects and
eNO measurements, steroid naı¨ve subjects were included.
In daily practice general practitioners often start inhaled
corticosteroid (ICS) therapy and subsequently refer to the
pulmonologist. Therefore, the diagnostic quality of eNO in
an unselected sample remains to be assessed.
This study examines the diagnostic role of eNO in
comparison with the histamine provocation test and FEV1-
reversibility, in two unselected samples of new referrals to
a pulmonary outclinic from two different hospitals.
Methods
Centres
Two centres were involved in this study: the Spaarne
Hospital, Hoofddorp, the Netherlands, which is a hospital
serving the general community and the University Medical
Center,Utrecht, theNetherlands (UMCU),which is a referral-
type hospital, but also serves the general community.
Subjects
Random samples from all newly referred outpatients were
drawn before a diagnosis wasmade. Immediately after a first
visit to the outpatient clinic, subjects were invited to
undergo full lung function testing, includingmeasurement of
the eNO levels and histamine provocation thresholds.
Current medication was not a selection criterion, nor age or
sex. Only those subjects referred for a suspected diagnosis in
which measurement of eNO clearly is of no value were
excluded (e.g. lung cancer). Subjects referred for a second
opinion or in whom a diagnosis was already established were
also excluded. Subjects gave written informed consent and
the local medical ethical committees approved the study.
Pulmonary function measurements
Total lung capacity (TLC) and residual volume (RV) were
determined by whole body plethysmography andspirometry/flow-volume curves via pneumotachography
(Jaeger, Wurzburg and ZAN, Oberthulba, both in Germany)
according to ERS-guidelines.14 The VA (alveolar volume), via
single breath methane dilution, was measured as part of
the determination of the TLCO (Transfer factor of the lung
for carbon monoxide).
At arrival, subjects first rested for 15 min after which
the baseline lung function was determined. Three consec-
utive spirometry/flow-volume curves measurements were
done and the flow-volume loop with the highest value of
the FVC and FEV1 was selected. Measurement of the bron-
chodilator response was done on a protocol basis.14 On
a second visit the eNO, allergy test and bronchoprovocation
test was done consecutively. Patients refrained from using
short-acting and long-acting bronchodilators 8 or 12 h prior
to testing, respectively. All subjects received 400 mg sal-
butamol via MDI plus a spacer device, 15 min later
spirometry was repeated, to measure/determine
reversibility.
Measurement of exhaled NO
ENO measurements were performed in accordance with the
ERS/ATS guidelines.15 In the UMCU eNO levels were
measured with a ECO MEDICS CLD 88 in conjunction with
DENOX 88 (Eco Physics, Du¨rnten, Switserland). For
measurements of eNO the subjects exhaled from total lung
capacity to residual volume. The exhalation was controlled
with a biofeedback monitor, and the subjects were asked to
control the flow at 50 ml/s. Total exhalation time was 12 s.
NO as well as CO2 were measured. The point at which the
CO2 level reached 90% of its maximum was taken to
determine the average NO over the next 5 s. Average of
three measurements within 5% of each other were taken.
In the Spaarne Hospital eNO was measured with the Niox
Mino device (Aerocrine, New Providence, United States of
America), in which the NO is measured with an electro-
chemical cell, using an exhalation flow of 50 ml/s, with
a total exhalation time of 10 s.
Measurement of histamine hyperresponsiveness
In the UMCU histamine diphosphate was administered using
a DeVilbiss no. 646 handheld nebuliser (DeVilbiss Health
Care Inc. Somerset, PA) in doubling doses from 0.25 to
16 mg/ml. Histamine and phosphate-buffered saline acted
as positive and negative controls, respectively. The test
was stopped at the moment the FEV1 fell by more than 20%.
Salbutamol aerosol was administered to aid recovery. The
concentration of histamine that provoked a 20% fall in FEV1
(PC20) was estimated by interpolation. Airway hyper-
responsiveness was defined as a PC20 of <8 mg/ml.
In the Spaarne hospital the same protocol was used, with
a Spira Dosimeter (Spira Respiratory Care Center,
Ha¨meenlinna, Finland), measurements were made on Vmax
Spectra 20 (Jaeger, Bilthoven, The Netherlands).
Skin prick testing
Sensitization to common allergens was measured by skin
prick test reactions on the volar side of the forearm. In the
UMCU fourteen allergens were tested (ALK-Abello AS
Nieuwegein Netherlands). Mixed grasses 10.000 BU/ml,
Mugwort (Artemisia vulgaris) 10.000 BU/ml, Mixed Tree
pollen (birch, alder and hazel) 10.000 BU/ml, Dog (Canis
Table 1 List of non-asthmatic diagnosis.
Spaarne UMCU
Disease % %
Cough 25.0 19.3
COPD 6.8 18.5
Not obtained/Not specified 28.4 28.1
Sarcoidosis 4.5 3.7
Pleural disease 2.3 3.0
Pneumonia 10.2 3.0
Bronchiectasis 3.4 2.2
Hyperventilation 2.3 1.5
System disease 0 1.5
Pulmonary Embolism 2.3 0.7
Mesothelioma 0 0.7
Tumour 1.1 0.7
Vascular disease 0 0.7
Miscellaneous 13.6 16.4
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10.000 BU/ml, Horse (Equus caballus) 10.000 BU/ml,
Aspergillus Fumigatus 1:20 g/v, House dust mites (Derm.
Pteronyssinus and Derm. Farinae) 10.000 BU/ml, Cavia
(Cavia porsellus) 1:100 g/v, Rabbit (Oryctolagus cuniculus)
1:100 g/v, Parakeet (Melopsittacus undulatus) 1:20 g/v.
Histamine and glycerol acted as positive and negative
controls, respectively. In the Spaarne hospital only the first
8 allergens were used, also with positive and negative
controls.
A positive reaction was defined as a 3 mm wheal or
greater diameter 15 min after skin prick.
Parameters
The following items were scored via an interview:
1) use of inhaled steroids (drug, dose and type of
inhaler)16
2) use of nitrate rich food <24 h (amount and time past
since meal)11
3) respiratory infections <6 weeks (presence and
duration)15
4) smoking (pack years)17,18Table 2 Descriptive data (mean, sd) of all subjects
(NZ 362) in the study (*Z as percentage predicted).
No asthma Asthma p-value
Age (years) 51.2 (12.7) 45.0 (11.0) <0.001
Predilator FEV1* 96.3 (18.9) 90.1 (16.1) 0.014
FEV1/IVC 76.0 (9.6) 74.4 (10.2) 0.252
FEV1-reversibility* 4.1 (5.2) 6.7 (6.1) 0.003
TLC* 105.0 (13.9) 103.8 (12.7) 0.525
RV* 111.6 (28.3) 112.3 (28.5) 0.876
Tlco* 82.6 (19.0) 84.6 (16.0) 0.449Diagnosis
The diagnosis, initially made by the treating physician, was
reviewed by a panel of three independent pulmonologists.
The diagnosis ‘asthma’ was based on integrative assessment
of medical history, pulmonary function testing and bronchial
hyperresponsiveness tests. Those not suffering from asthma
were labelled as ‘no asthma’. The eNO levels were not
reported to the treating physician or to the panel, all other
lung function parameters were available. Next to lung
function testing, all other diagnostic measures were allowed
and chosen at the discretion of the treating physician.
Statistics
We calculated means, standard deviations and 95% confi-
dence intervals (CI) for normal distributed parameters and
medians with 25%/75% quartiles for non-normal distributed
ones. The eNO levels were ln-transformed to obtain
a normal distributed parameter. Allergy, inhaled steroid
use, use of nitrate rich food, respiratory infections and
smoking were converted to either present (1) or absent (0).
The effects on eNO-, PC20 and FEV1-reversibility of the
above parameters were approached by unpaired T-tests.
Logistic regression was subsequently used to calculate the
probability to be an asthmatic: eNO-, PC20 or FEV1-revers-
ibility were the primary variables of interest. The presence
of allergy, the use of inhaled steroids, the use of nitrate
rich food, respiratory infections and smoking were consid-
ered as modifiers in the logistic regression analysis, as well
as sex. Having obtained the probabilities, receiver operator
curves (ROC) were constructed and the area under this
curve estimated (which can be considered as the proba-
bility to make a correct diagnosis of the absence or pres-
ence of asthma). These areas were compared for statisticalsignificant differences via the method of Metz using that of
the PC20 as reference test.
19
Results
Subjects
In the Spaarne hospital 143 subjects were included of which
55 (38,5%) were labelled as ‘asthmatic’ by the panel. In the
UMCU 219 subjects were included of which 85 (38,8%) were
labelled as ‘asthmatic’. The non-asthmatic diagnoses are
depicted in Table 1.
In Table 2 the descriptive data of the subjects are dis-
played. The asthmatic group on both samples used inhaled
steroids more frequently (p< 0.001), was more allergic
(p< 0.001) and contained slightly less males in the UMCU
(pZ 0.025). However, the number of recent infections, or
the use of nitrate food were all non-significantly different
between the groups (data not shown). In the Spaarne
Hospital the asthmatics were mostly non-smokers
(pZ 0.004), whereas in the UMCU no difference could be
found.
Comparison of eNO, PC20 and FEV1-reversibility
Although the eNO levels were slightly higher in the Spaarne
hospital compared to the UMCU, no significant parame-
ter*hospital interaction or centre effect could be found for
Table 3 Effect of various conditions on FEV1-reversibility, eNO levels (ln-transformed) and PC20.
Parameter FEV1-reversibility Exhaled NO (ln ppb) PC20
Mean sd p Mean sd p Median p
Asthma No 4.13 5.16 0.003 2.56 0.75 0.001 10.54 <0.001
Yes 6.75 6.07 2.91 0.78 2.97
Allergy No 5.11 5.98 0.725 2.54 0.72 0.001 8.00 0.053
Yes 5.42 5.12 2.88 0.81 5.65
Use of inhaled steroids No 5.11 5.49 0.863 2.79 0.76 0.010 6.60 0.829
Yes 5.27 6.01 2.51 0.79 5.80
Recent infection No 5.39 6.00 0.358 2.64 0.80 0.073 6.90 0.096
Yes 4.45 4.40 2.86 0.71 5.29
Smoking No 5.45 5.94 0.152 2.78 0.74 <0.001 7.55 0.027
Yes 3.79 3.86 2.18 0.82 4.40
Use of nitrate rich food No 5.41 5.75 0.336 2.65 0.78 0.116 7.08 0.669
Yes 4.43 5.42 2.84 0.75 5.67
Sex Female 4.57 5.87 0.190 2.52 0.72 <0.001 5.04 0.012
Male 5.71 5.46 2.87 0.80 8.00
804 P. Munnik et al.eNO as well as the other parameters in the analysis: the
differences between the yes/no groups hence do not differ
between the two centres, therefore the data were pooled.
The ln-transformed eNO levels are statistically signifi-
cant higher in asthma and allergy, lower in inhaled steroids
users and smokers. The median PC20-levels were statisti-
cally significant lower in asthma and smokers. The FEV1-
reversibility was higher only in asthmatics (see Table 3).
Diagnostic quality of exhaled NO, PC20 and FEV1-
reversibility
Logistic regression was used to calculate the probability of
being diagnosed as ‘asthmatic’, based on eNO, PC20 and
FEV1-reversibility. Allergy, use of inhaled steroids, recent
infection, smoking, sex and the use of nitrate food were
incorporated into the analysis as influencing factors. The
resulting area under the ROC curve serves as main
comparator (see Table 4) and the PC20 as the reference
test.
As the findings from both centres were very similar we
pooled the data to assess the equivalence between the
methods under investigation. The differences between the
PC20 area on one hand and the corrected eNO levels or
FEV1-reversibility on the other were non-significant (see
Table 5). When we compared eNO without a correction for
the modifiers, it turned to be significantly lower than the
PC20 ROC area (Fig. 1).Table 4 Area under the ROC for PC20, eNO, uncorrected eNO
denotes the probability to make a correct diagnosis of the abse
maximal 1); the p-value denotes the outcome of the comparison
Spaarne
AUC ROC
PC20 0.874
eNO (corrected) 0.826
FEV1-reversibility 0.805
eNO (uncorrected) 0.635Discussion
Summary
This study showed that eNO, FEV1-reversibility and the PC20
can equally well discriminate asthma from non-asthma in
unselected and frequently steroid-using population of new
referred subjects to a pulmonary outclinic, only when eNO
levels are corrected for the influence of its modifiers. This
finding is present in an academic teaching hospital as well
as in a general hospital. Without correcting for the nuisance
factors, eNO is not a very usable tool in the diagnosis of
asthma in this population.
Explanation
As said in the introduction, several eNO level modifiers are
known and this study clearly confirms their effects in
a group of unselected new referrals. Based on these find-
ings and the underlying literature, we consider the effects
of these modifiers as consistent and predictable and so the
possibility emerges to correct for such modifiers.
Standard statistical methods, like logistic regression,
offer validated approaches to correct for the influence of
such modifiers: the effects of, e.g., medication and allergy
can be accounted for. This will only expand the usability of
eNO and makes exclusion of inhaled steroid users unnec-
essary. The alternative, to wash-out inhaled steroids andand FEV1-reversibility (as percent predicted). The AUC ROC
nce or presence of asthma (scaled between minimal 0.5 and
versus an AUC of 0.5, which indicates a useless test.
UMCU
p-value AUC ROC p-value
<0.001 0.832 <0.001
<0.001 0.821 <0.001
<0.001 0.828 <0.001
<0.001 0.641 0.002
Table 5 Comparison of AUC ROC curve of eNO, uncor-
rected eNO and FEV1-reversibility (as percent predicted)
using the PC20 AUC ROC as reference test (pooled data). The
95% CI is the confidence interval of the differences between
the PC20 AUC ROC on one hand and the other parameters
AUC ROC on the other. See Table 4 for AUC ROC values.
p-value 95% confidence interval
lower bound Upper bound
eNO 0.665 0.043 0.067
eNO (uncorrected) <0.001 0.110 0.320
FEV1-reversibility 0.654 0.041 0.065
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because it requires patients to refrain weeks from inhaled
steroids. Similar goes for smoking, nitrate rich food and
infections, while the presence of allergy cannot be avoi-
ded. When such requirements are necessary, the eNO test
becomes hard to use in daily practice.
Logistic regression model
The relationship between eNO and inhaled steroids is
a doseeresponse relationship, but we here used the
straightforward presence or absence of ICS use as nuisance
parameter. The drawback of modelling doseeresponse
curves is the necessity for very large sample sizes to obtain
sufficient power to cope with the range of dosages, the
types of drugs and inhalers. A rule of thumb requires for
each variable inserted into the analysis at least 20 cases.
This disadvantage could be solved by converting drugs,
doses and inhalers to a standard drug/dose/inhaler (e.g.Figure 1 ROC curves of PC20, eNO, uncorrected eNO and
FEV1-reversibility (as percent predicted).beclomethasone dose equivalents), but that is a hazardous
approach.
The approach taken here was to categorize ICS use into
‘yes/no’, an approach often used in epidemiology and in
eNO research.20 The implicit assumption is that ICS lower
eNO levels to a maximum degree irrespective of drug-
potency, -dose and type of inhaler. This might well be the
case when the reduction of eNO by steroids is an all-or-
nothing phenomenon: when a low dose of ICS (lower than
used in daily routine) already lowers eNO by a significant
amount and higher doses not any further (Zdoseeresponse
curve with an early plateau-phase), this requirement is
fulfilled and the approach is valid. We feel that this is the
case as several studies did show this phenomenon. In
a randomized study in asthmatics Dal Negro could not show
differences in eNO-response to 100 mg or 400 mg bid beclo-
methasone.16 Kharitonov compared 100 mg and 400 mg
budesonide and found differences between the dose-groups
after 2 weeks of ICS: mean reduction 6.5 ppb versus 5.3 ppb
after 400 mg and 100 mg budesonide.21 In a study by Silkoff
the conclusion was that in a low baseline eNO-group (60e
100 ppb) 100 mg beclomethasone elicited a modest change,
but that higher doses did not lower the eNO any further.22
Only in the high eNO-group (>100 ppb) a doseeresponse
relation with doses >100 mg was visible. Jatakanon inves-
tigated the effect of increasing budesonide doses on eNO
and reported on 100 mg a 0.2 fold change, while on 400 mg
and 1600 mg a 0.6 and respectively a 0.5 fold change
occurred.23Validation
The diagnosis of asthma, of course, plays an important role
in this study. Despite the fact that a panel reviewed the
diagnosis, it is realized that mistakes are still possible. This
causes an imperfect standard bias and this error lowers the
sensitivity and specificity of all test methods under evalu-
ation. In our case the sensitivity and specificity of exhaled
NO and PC20, etc., would be lowered. Here, the imperfect
standard bias is of course not known because a true gold
standard is lacking. We however compared several test
methods within the same database. With the same imper-
fect standard bias for all, the correction factor will be
exactly the same for all tests and the resulting ranking is
therefore valid.
Extrapolation and interpretation
The extrapolation of diagnostic studies can be influenced
by several problems. We first of all tried to avoid selection
bias by randomly inviting new referred subjects before
a diagnosis was made: the effect of season, of treating
physicians, etc. is minimized in that way. Next to this the
sample size (case/variable ratio >20:1) of the study and
the a priori selection of modifiers also safeguards against
biased outcomes. We therefore feel that our findings can be
extrapolated, also because in two centres the findings and
comparisons turned out to be very similar.
Still we must emphasize that cut-off values are system-
dependent. Because of the fact that eNO levels in the
Spaarne hospital were always slightly higher compared to
806 P. Munnik et al.the UMCU-levels based on systemic instrument differences,
the discriminatory power of eNO in the two hospitals is
similar but cut-off values will show the same systemic
difference. Therefore, we did not supply formulas for
correction of the eNO levels.
Our results are in good accordancewith the recent findings
of Dressel et al.,24 who did find an influence on eNO of
smoking, respiratory tract infection, height, gender and atopy
in a large cohort of subjects (steroid users were excluded).
The authors advised to correct eNO for these factors.
Several studies found a stronger correlation between
atopy (also ‘‘extrapulmonary’’) and eNO levels, than
asthma and eNO levels,9,25 although eNO levels were not ln-
transformed in these studies. On the other hand, Dressel
et al.24 found no interaction between respiratory allergy,
sex, gender, smoking and recent respiratory tract infection
in log transformed eNO levels in steroid naı¨ve subjects, and
created a correction formula for eNO based on these
parameters. In the introduction we quoted some studies in
favour of using eNO to guide asthma treatment, recently
some papers were published that showed no benefit of
using eNO in the clinical setting for guiding therapy.4,26 In
these two studies eNO levels were not corrected for
nuisance factors. It would be interesting to re-assess this
study with eNO levels corrected for nuisance factors.
Berkman et al.12 concluded that eNO was ‘as good as
bronchial provocation tests’ in diagnosing asthma, in a very
well defined population excluding those with ICS use,
obstructive pattern, and significant reversibility. Further-
more, the subjects included were already considered to be
possible asthmatics by the referring physician.12 The same
selection bias due to exclusion of subjects on ICS and the
inclusion of only subjects highly suspective of being asth-
matics was present in the study of Dupont.13 These bias
leads to difficulty in implementation of the results of these
two studies in clinical practice.
Rationale of selected methods
Based on the comparison as depicted in Tables 4 and 5 one
can assess the relative merits of the methods. The FEV1-
reversibility, the PC20 and the corrected eNO-method seem
to be equivalent in their capability to diagnose asthma, as
their areas under the ROC curve are very comparable.
Choosing any of the three methods will deliver the same
diagnostic quality. So secondary arguments can be added to
the equation, when taking a decision which method to
prefer. The advantage of the eNO-method is the quick and
non-invasive character, but one needs to correct for
modifiers. That isn’t needed for the FEV1-reversibility and,
to a lesser extent, for the PC20. Of the three methods the
PC20 is the one which is most cumbersome to the patient
and requires most time: one could therefore view upon this
method as least suitable for daily practice use. Based on
the minor effect of modifiers on the FEV1-reversibility, this
method is the least complicated.In conclusion
The measurement of the eNO level is a non-invasive, safe
and quick diagnostic for asthma, even in subjects usinginhaled steroids, under the condition that a correction for
allergy, use of inhaled steroids, recent infection, smoking,
sex and the use of nitrate food has been made. In unse-
lected subjects, it is capable of separating asthma from
non-asthma comparable to the FEV1-reversibility.
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